Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Current and future therapies for targeting HER2 mutations in gastrointestinal cancer.

Expert review of anticancer therapy - 1 Nov 2018

El Dika Imane, Ilson David H

Abstract excerpt

INTRODUCTION: Gastrointestinal (GI) cancers altogether represent the most common cancer type. HER2 is found to be present in nearly all histologic types of GI cancers in variable degrees of expression. Over the last decade, substantial advances have been made in targeting HER2-positive cancers. Areas covered: The present review summarizes the current progress and future directions for HER2 targeted therapies in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Resistance, Neoplasm
Share to Gastrointestinal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Mutation

Share to Neoplasm Staging

Share to Receptor, ErbB-2

Share to Trastuzumab

Source

Identifiers

PMID: 30092682
DOI: 10.1080/14737140.2018.1510324

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Current and future therapies for targeting HER2 mutations in gastrointestinal cancer.PMID 30092682Read ↗

Targeting ERBB2/HER2 genetic alterations: an expanding therapeutic opportunity in gastrointestinal cancers.Semantic proximity Read ↗

HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists.Semantic proximity Read ↗

HER2 in Metastatic Colorectal Cancer: Pathology, Somatic Alterations, and Perspectives for Novel Therapeutic SchemesSemantic proximity Read ↗

Clinical impact of tumour biology in the management of gastroesophageal cancer.Semantic proximity Read ↗

The genomics and therapeutics of HER2-positive gastric cancer—from trastuzumab and beyondSemantic proximity Read ↗

Established and Potential Predictive Biomarkers in Gastrointestinal Cancer--c-Kit, Her2, Ras and Beyond.Semantic proximity Read ↗

A Comprehensive Review of HER2 in Cancer Biology and TherapeuticsSemantic proximity Read ↗

A Comprehensive Review of HER2 in Cancer Biology and TherapeuticsSemantic proximity Read ↗

HER2 in solid tumors: more than 10 years under the microscope; where are we now?Semantic proximity Read ↗

HER2 targeted therapy in colorectal cancer: New horizons.Semantic proximity Read ↗

Translating genomic profiling to gastrointestinal cancer treatment.Semantic proximity Read ↗

Activating HER2 mutations as emerging targets in multiple solid cancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.